Posted by Michael Wonder on 11 Dec 2017
Drug makers continue to owe FDA numerous clinical trials
7 December 2017 - Under various circumstances, the FDA may require a drug maker to run a post-marketing study, but a large percentage of these studies are still pending, according to the latest agency analysis.
As of the end of fiscal year 2016, 86% of required studies were still pending, which meant they were not yet under way. An average of 261 post-marketing requirements were made each year since fiscal year 2010, and most that were established several years ago were since fulfilled or released.
